Alnylam Pharmaceuticals Gets Bullish Rating, Five New Stock Coverages on Wednesday

Top Wall Street analysts have changed their views on these popular stocks. For the full list of all analyst rating changes, including upgrades, downgrades, and new coverages, please refer to our analyst ratings page.

BMO Capital analyst David Lebowitz initiated coverage on Alnylam Pharmaceuticals, Inc. with an Outperform rating and a price target of $318. Alnylam Pharmaceuticals closed Tuesday at $228.61. See what other analysts think about the stock.

Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on Agomab Therapeutics NV with an Overweight rating. AgomAb Therapeutics stock closed Tuesday at $13.73. See what other analysts think about the stock.

BMO Capital analyst David Lebowitz initiated coverage on Biomarin Pharmaceutical Inc with an Outperform rating and a price target of $98. BioMarin Pharmaceutical closed Tuesday at $66.99. See what other analysts think about the stock.

CLSA analyst Alvin Huang initiated coverage on KE Holdings Inc – ADR with an Outperform rating and a price target of $23.8. KE Holdings stock closed Tuesday at $16.87. See what other analysts think about the stock.

BMO Capital analyst David Lebowitz initiated coverage on Ionis Pharmaceuticals Inc with a Market Perform rating and a price target of $60. Ionis Pharmaceuticals closed Tuesday at $59.62. See what other analysts think about the stock.

Considering buying ALNY stock? Here's what analysts think.